Drug Profile
Research programme: neurodegenerative disorders therapies - Compass Biomedical
Latest Information Update: 27 Dec 2016
Price :
$50
*
At a glance
- Originator Arteriocyte
- Class Cell therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Neurodegenerative disorders
Most Recent Events
- 12 Dec 2016 Arteriocyte is now called Compass Biomedical
- 21 Jan 2011 Discontinued for Neurodegenerative disorders in USA (unspecified route)
- 16 Jan 2008 Early research in Neurodegenerative disorders in USA (unspecified route)